News
BCYC
5.33
+3.70%
0.19
Weekly Report: what happened at BCYC last week (0406-0410)?
Weekly Report · 4d ago
Bicycle Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 04/08 13:39
Bicycle Therapeutics Price Target Cut to $12.00/Share From $13.00 by Morgan Stanley
Dow Jones · 04/08 13:39
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12
Benzinga · 04/08 13:29
Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
TipRanks · 04/08 11:55
Top Executives Quietly Cash Out at Bicycle Therapeutics
TipRanks · 04/07 02:02
Bicycle Therapeutics COO Jennifer Scott Perry disposes of shares worth $6,803
Reuters · 04/06 22:30
Weekly Report: what happened at BCYC last week (0330-0403)?
Weekly Report · 04/06 09:11
Bicycle Therapeutics announces annual general meeting, issues proxy statement
Reuters · 04/03 20:08
Weekly Report: what happened at BCYC last week (0323-0327)?
Weekly Report · 03/30 09:11
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
TipRanks · 03/27 20:35
Bicycle Therapeutics files initial beneficial ownership statement; COO Jennifer Scott Perry reports 93,872 ordinary shares
Reuters · 03/25 22:08
Weekly Report: what happened at BCYC last week (0316-0320)?
Weekly Report · 03/23 09:11
Bicycle Therapeutics Price Target Cut to $36.00/Share From $44.00 by Oppenheimer
Dow Jones · 03/18 16:27
Bicycle Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/18 16:27
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36
Benzinga · 03/18 16:17
Bicycle Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 03/18 14:13
Bicycle Therapeutics Price Target Cut to $7.00/Share From $11.00 by RBC Capital
Dow Jones · 03/18 14:13
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7
Benzinga · 03/18 14:03
Bicycle Therapeutics Price Target Cut to $8.00/Share From $12.00 by Citizens
Dow Jones · 03/18 12:57
More
Webull provides a variety of real-time BCYC stock news. You can receive the latest news about Bicycle Therapeutics Limited through multiple platforms. This information may help you make smarter investment decisions.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.